Jawad Fares1, Atique U Ahmed1, Ilya V Ulasov1, Adam M Sonabend1, Jason Miska1, Catalina Lee-Chang1, Irina V Balyasnikova1, James P Chandler1, Jana Portnow2, Matthew C Tate1, Priya Kumthekar3, Rimas V Lukas3, Sean A Grimm3, Ann K Adams4, Charles D Hébert5, Theresa V Strong6, Christina Amidei1, Victor A Arrieta1, Markella Zannikou1, Craig Horbinski7, Hui Zhang8, Kirsten Bell Burdett8, David T Curiel9, Sean Sachdev10, Karen S Aboody11, Roger Stupp1, Maciej S Lesniak12. 1. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 2. Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, CA. 3. Department of Neurology, Division of Neuro-Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 4. Office of the Vice-President for Research, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 5. Southern Research Institute, Birmingham, AL, USA. 6. Foundation for Prader-Willi Research, Walnut, CA, USA. 7. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA; Department of Pathology, Division of Neuropathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 8. Department of Preventive Medicine, Division of Biostatistics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 9. Department of Radiation Oncology, Washington University School of Medicine in Saint Louis, MO, USA. 10. Department of Radiation Oncology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. 11. Department of Developmental & Stem Cell Biology, Division of Neurosurgery, City of Hope, Duarte, CA. 12. Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. Electronic address: maciej.lesniak@northwestern.edu.
Abstract
BACKGROUND: Malignant glioma is the most common and lethal primary brain tumour, with dismal survival rates and no effective treatment. We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma. METHODS: This was a first-in-human, open-label, phase 1, dose-escalation trial done to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3 + 3 design. Patients with newly diagnosed, histologically confirmed, high-grade gliomas (WHO grade III or IV) were recruited. After neurosurgical resection, NSC-CRAd-S-pk7 was injected into the walls of the resection cavity. The first patient cohort received a dose starting at 6·25 × 1010 viral particles administered by 5·00 × 107 NSCs, the second cohort a dose of 1·25 × 1011 viral particles administered by 1·00 × 108 NSCs, and the third cohort a dose of 1·875 × 1011 viral particles administered by 1·50 × 108 NSCs. No further dose escalation was planned. Within 10-14 days, treatment with temozolomide and radiotherapy was initiated. Primary endpoints were safety and toxicity profile and the maximum tolerated dose for a future phase 2 trial. All analyses were done in all patients who were included in the trial and received the study treatment and were not excluded from the study. Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. FINDINGS: Between April 24, 2017, and Nov 13, 2019, 12 patients with newly diagnosed, malignant gliomas were recruited and included in the safety analysis. Histopathological evaluation identified 11 (92%) of 12 patients with glioblastoma and one (8%) of 12 patients with anaplastic astrocytoma. The median follow-up was 18 months (IQR 14-22). One patient receiving 1·50 × 108 NSCs loading 1·875 × 1011 viral particles developed viral meningitis (grade 3) due to the inadvertent injection of NSC-CRAd-S-pk7 into the lateral ventricle. Otherwise, treatment was safe as no formal dose-limiting toxicity was reached, so 1·50 × 108 NSCs loading 1·875 × 1011 viral particles was recommended as a phase 2 trial dose. There were no treatment-related deaths. The median progression-free survival was 9·1 months (95% CI 8·5-not reached) and median overall survival was 18·4 months (15·7-not reached). INTERPRETATION: NSC-CRAd-S-pk7 treatment was feasible and safe. Our immunological and histopathological findings support continued investigation of NSC-CRAd-S-pk7 in a phase 2/3 clinical trial. FUNDING: US National Institutes of Health.
BACKGROUND: Malignant glioma is the most common and lethal primary brain tumour, with dismal survival rates and no effective treatment. We examined the safety and activity of NSC-CRAd-S-pk7, an engineered oncolytic adenovirus delivered by neural stem cells (NSCs), in patients with newly diagnosed high-grade glioma. METHODS: This was a first-in-human, open-label, phase 1, dose-escalation trial done to determine the maximal tolerated dose of NSC-CRAd-S-pk7, following a 3 + 3 design. Patients with newly diagnosed, histologically confirmed, high-grade gliomas (WHO grade III or IV) were recruited. After neurosurgical resection, NSC-CRAd-S-pk7 was injected into the walls of the resection cavity. The first patient cohort received a dose starting at 6·25 × 1010 viral particles administered by 5·00 × 107 NSCs, the second cohort a dose of 1·25 × 1011 viral particles administered by 1·00 × 108 NSCs, and the third cohort a dose of 1·875 × 1011 viral particles administered by 1·50 × 108 NSCs. No further dose escalation was planned. Within 10-14 days, treatment with temozolomide and radiotherapy was initiated. Primary endpoints were safety and toxicity profile and the maximum tolerated dose for a future phase 2 trial. All analyses were done in all patients who were included in the trial and received the study treatment and were not excluded from the study. Recruitment is complete and the trial is finished. The trial is registered with ClinicalTrials.gov, NCT03072134. FINDINGS: Between April 24, 2017, and Nov 13, 2019, 12 patients with newly diagnosed, malignant gliomas were recruited and included in the safety analysis. Histopathological evaluation identified 11 (92%) of 12 patients with glioblastoma and one (8%) of 12 patients with anaplastic astrocytoma. The median follow-up was 18 months (IQR 14-22). One patient receiving 1·50 × 108 NSCs loading 1·875 × 1011 viral particles developed viral meningitis (grade 3) due to the inadvertent injection of NSC-CRAd-S-pk7 into the lateral ventricle. Otherwise, treatment was safe as no formal dose-limiting toxicity was reached, so 1·50 × 108 NSCs loading 1·875 × 1011 viral particles was recommended as a phase 2 trial dose. There were no treatment-related deaths. The median progression-free survival was 9·1 months (95% CI 8·5-not reached) and median overall survival was 18·4 months (15·7-not reached). INTERPRETATION: NSC-CRAd-S-pk7 treatment was feasible and safe. Our immunological and histopathological findings support continued investigation of NSC-CRAd-S-pk7 in a phase 2/3 clinical trial. FUNDING: US National Institutes of Health.
Authors: Ashish H Shah; Anil Mahavadi; Long Di; Alexander Sanjurjo; Daniel G Eichberg; Veronica Borowy; Javier Figueroa; Evan Luther; Macarena Ines de la Fuente; Alexa Semonche; Michael E Ivan; Ricardo J Komotar Journal: J Neurooncol Date: 2020-07-05 Impact factor: 4.130
Authors: E Antonio Chiocca; Khalid M Abbed; Stephen Tatter; David N Louis; Fred H Hochberg; Fred Barker; Jean Kracher; Stuart A Grossman; Joy D Fisher; Kathryn Carson; Mark Rosenblum; Tom Mikkelsen; Jeff Olson; James Markert; Steven Rosenfeld; L Burt Nabors; Steven Brem; Surasak Phuphanich; Scott Freeman; Rick Kaplan; James Zwiebel Journal: Mol Ther Date: 2004-11 Impact factor: 11.454
Authors: K S Aboody; A Brown; N G Rainov; K A Bower; S Liu; W Yang; J E Small; U Herrlinger; V Ourednik; P M Black; X O Breakefield; E Y Snyder Journal: Proc Natl Acad Sci U S A Date: 2000-11-07 Impact factor: 11.205
Authors: Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp Journal: N Engl J Med Date: 2005-03-10 Impact factor: 91.245
Authors: Frederick F Lang; Janet M Bruner; Gregory N Fuller; Kenneth Aldape; Michael D Prados; Susan Chang; Mitchel S Berger; Michael W McDermott; Sandeep M Kunwar; Larry R Junck; William Chandler; James A Zwiebel; Richard S Kaplan; W K Alfred Yung Journal: J Clin Oncol Date: 2003-07-01 Impact factor: 44.544
Authors: Alex L Tobias; Bart Thaci; Brenda Auffinger; Esther Rincón; Irina V Balyasnikova; Chung Kwon Kim; Yu Han; Lingjiao Zhang; Karen S Aboody; Atique U Ahmed; Maciej S Lesniak Journal: Stem Cells Transl Med Date: 2013-08-07 Impact factor: 6.940
Authors: Ilya V Ulasov; Zeng B Zhu; Matthew A Tyler; Yu Han; Angel A Rivera; Andrey Khramtsov; David T Curiel; Maciej S Lesniak Journal: Hum Gene Ther Date: 2007-07 Impact factor: 5.695
Authors: Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad Journal: Br J Cancer Date: 2022-06-04 Impact factor: 9.075
Authors: Jennifer Batalla-Covello; Hoi Wa Ngai; Linda Flores; Marisa McDonald; Caitlyn Hyde; Joanna Gonzaga; Mohamed Hammad; Margarita Gutova; Jana Portnow; Tim Synold; David T Curiel; Maciej S Lesniak; Karen S Aboody; Rachael Mooney Journal: Cancers (Basel) Date: 2021-12-16 Impact factor: 6.639